Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVT-22832
- Development stage
- Preclinical
- Lead developer
- Laboratorios Salvat
- Modality
- Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
SVT-22832 is a moisturizing nasal spray developed by Laboratorios Salvat, utilizing a smart polymer formulation to provide relief for dry and irritated nasal passages. It is designed to form a protective barrier or film on the nasal mucosa, offering symptomatic relief for conditions such as the common cold, sinusitis, and allergies. The product is currently in the development phase and is characterized by its ease of use as a spray compared to other moisturizing formats. Its mechanism of action is primarily physical, acting as a moisturizing agent and barrier rather than a traditional pharmacological agent.
Beyond the preview
Go deeper on SVT-22832.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVT-22832.